network member

New Jersey

About Network Member

Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Cancer areas:Breast

Fred & Pamela Buffett Cancer Center

New York University Cancer Institute

Orlando Health Cancer Institute

Parkview Research Center

Penn State Cancer Institute

Providence Cancer Institute

Rutgers Cancer Institute of New Jersey

The Ohio State University

Tufts Medical Center

University of Alabama at Birmingham Comprehensive Cancer Center

University of Arizona Cancer Center

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Michigan Health-West

University of Michigan Rogel Cancer Center

University of Virginia Cancer Center

University of Wisconsin Carbone Cancer Center

Virginia Commonwealth University

See clinicaltrials.gov

Currently Enrolling

HCRN-BSK22-562

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)

Cancer areas:Basket

AdventHealth Orlando

CARTI

John Theurer Cancer Center at Hackensack Meridian Health

Meritus Center for Clinical Research / John R. Marsh Cancer Center

Salinas Valley Health

University of Louisville / James Graham Brown Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

University of South Florida

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Deepak Kilari

Cancer areas:Bladder

Froedtert & the Medical College of Wisconsin

John Theurer Cancer Center at Hackensack Meridian Health

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University of Rochester Medical Center - Wilmot Cancer Institute

Vanderbilt-Ingram Cancer Center

Virginia Commonwealth University

See clinicaltrials.gov

Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Columbia University Irving Medical Center

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

John Theurer Cancer Center at Hackensack Meridian Health

Moores Cancer Center at UC San Diego Health

Penn Medicine Abramson Cancer Center

The Ohio State University

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Weill Cornell Medicine

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Currently Enrolling

BTCRC-GI22-588

A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Cancer areas:Anal

Rutgers Cancer Institute of New Jersey

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Greg Durm

Cancer areas:Lung

Fred & Pamela Buffett Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Masonic Cancer Center, University of Minnesota

Moffitt Cancer Center

Penn State Cancer Institute

Providence Cancer Institute

Rutgers Cancer Institute of New Jersey

The Ohio State University

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Virginia Cancer Center

Virginia Commonwealth University

See clinicaltrials.gov

Currently Enrolling

BTCRC-LYM20-463

A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Cancer areas:Lymphoma

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Rutgers Cancer Institute of New Jersey

The Ohio State University

University of Illinois Cancer Center

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GI16-288

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Darren R. Carpizo, Kristen Spencer

Cancer areas:Colorectal

Cleveland Clinic Cancer Center

Knight Cancer Institute at Oregon Health & Science University

Rutgers Cancer Institute of New Jersey

Sylvester Comprehensive Cancer Center at the University of Miami

The Ohio State University

University of Kansas Medical Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

Matthew D. Galsky

Cancer areas:Bladder Urothelial Carcinoma

Huntsman Cancer Institute at the University of Utah

Icahn School of Medicine at Mount Sinai

Rutgers Cancer Institute of New Jersey

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-LUN21-497

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Cancer areas:Lung

Barbara Ann Karmanos Cancer Center

Duke Cancer Institute

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Summit Health Cancer Center

University of Illinois Cancer Center

University of Virginia Cancer Center

See clinicaltrials.gov

Enrollment Closed

BTCRC-BRE16-042

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Nancy Chan

Cancer areas:Breast

Fred & Pamela Buffett Cancer Center

Michigan State University

New York University Cancer Institute

Rutgers Cancer Institute of New Jersey

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Enrollment Closed

BTCRC-GI15-067

A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067

Nelson Yee

Cancer areas:Pancreatic

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Penn State Cancer Institute

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Rutgers Cancer Institute of New Jersey

See clinicaltrials.gov

Enrollment Closed

BTCRC-GI20-457

A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457

Darren R. Carpizo, Kristen Spencer

Cancer areas:Liver and Bile Duct

DHR Health

Fred & Pamela Buffett Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

New York University Cancer Institute

Rutgers Cancer Institute of New Jersey

University of Illinois Cancer Center

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Enrollment Closed

BTCRC-LUN19-396

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Nasser H. Hanna

Cancer areas:Lung

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

New York University Cancer Institute

Penn State Cancer Institute

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Rutgers Cancer Institute of New Jersey

Summit Health Cancer Center

The Ohio State University

University of Virginia Cancer Center

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov